DrugPatentWatch Database Preview
Details for Patent: 9,561,217
» See Plans and Pricing
Which drugs does patent 9,561,217 protect, and when does it expire?
Patent 9,561,217 protects ESBRIET and is included in one NDA.
This patent has eleven patent family members in seven countries.
Summary for Patent: 9,561,217
| Title: | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
| Abstract: | A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. |
| Inventor(s): | Kiyonaka; Gakuji (Amagasaki, JP), Furuya; Yoshihiro (Amagasaki, JP), Suzuki; Yusuke (Amagasaki, JP) |
| Assignee: | INTERMUNE, INC. (Brisbane, CA) |
| Application Number: | 14/951,313 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,561,217 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; |
Drugs Protected by US Patent 9,561,217
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,561,217
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2001-019393 | Jan 29, 2001 |
International Family Members for US Patent 9,561,217
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 452637 | Start Trial | |||
| Germany | 60234812 | Start Trial | |||
| European Patent Office | 1356816 | Start Trial | |||
| Japan | 4077320 | Start Trial | |||
| Japan | WO2002060446 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
